XOMA Royalty names Jeffrey Trigilio CFO; Thomas Burns departs after ~19 years

XOMA Royalty Corp

Thomas Burns stepped down as CFO effective Jan 12, 2026; separation agreement includes $16k/month consulting for 3 months.
Jeffrey Trigilio appointed CFO effective Jan 12; was CFO/COO at Obsidian Therapeutics and CFO at Cullinan Therapeutics.
Trigilio receives $515k base salary, 40% target bonus, initial grant of 30,000 performance units, and annual equity grant in 2026.
Severance for Trigilio: 0.75x base salary, pro-rated bonus, 9-month health benefits; doubled to 1.5x base+bonus on change of control.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.